Delving into the Latest Updates on Lycopene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic DiseaseNeoplasmsInfectious Diseases+ [6]

Active Indication-

Inactive Indication

AneurysmCarcinogenesisCastration-Resistant Prostatic Cancer+ [11]

Originator Organization-

Active Organization-

Inactive Organization

Ospedale San Carlo di Nancy GVM Care e Research SrlCambridge Theranostics Ltd.Omicron Pharma SRL

+ [1]

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC40H56

InChIKeyOAIJSZIZWZSQBC-GYZMGTAESA-N

CAS Registry502-65-8

Previous results have been mixed as to whether the emulsifying agent lecithin increases carotenoid bioaccessibility and Caco-2 cellular uptake. The dose-response effect of lecithin (0-5 mg) on carotenoid bioaccessibility and Caco-2 cellular uptake was investigated in vitro using a mixture of β-carotene, lycopene, lutein, zeaxanthin and astaxanthin. Resulting micelles were incubated with Caco-2 cells for 4 h. Carotenoids in chyme, micelle, and cellular fractions were quantitated using HPLC-DAD and HPLC-MS/MS. Lecithin-micelle interactions were visualized using confocal microscopy. A lecithin dose of 1 mg improved carotenoid bioaccessibility ∼2× and led to increased Caco-2 cell uptake of the carotenes tested, but no change in xanthophylls tested, as compared to the control group (P < 0.05). Doses of lecithin ≥3 mg did not improve carotenoid bioaccessibility or Caco-2 cell uptake and produced oil droplet aggregation. These results suggest that limited doses of lecithin should be investigated in relation to maximizing carotenoid bioavailability in humans.

01 Mar 2025·Plant Foods for Human Nutrition

Nutraceutical Potential of Wild Leafy Vegetables Commonly Consumed by Tribal Communities: Cassia tora (L.) Roxb., Acalypha fruiticosa Forssk. and Talinum portulacifolium (Forssk.) Asch. ex Schweinf

Article

Author: Gomez, Saji ; Markose, Anu Mary ; Pathrose, Berin ; Jacob, Sharon ; Sharma, Manju V

Wide variety of consumable leafy vegetables are present in the nature but most of them are neither utilised nor scientifically investigated. Nutraceutical potential of these plants should be studied to enrich our knowledge, thus making them part of balanced diets. In view of this objective, three leafy vegetables were selected viz., Cassia tora (L.) Roxb., Acalypha fruiticosa Forssk. and Talinum portulacifolium (Forssk.) Asch. ex Schweinf. Phytochemical screening of the leaves collected from these plants was done in four solvents which revealed the presence of many secondary metabolites. Estimation of bioactive components revealed that the total phenolics (22.84 mgGAEg^-1), flavonoids (4.60 mgQEg^-1) and ascorbic acid (37.34 mg100g^-1) were accounted highest in C. tora whereas lycopene (12.61 mg100g^-1) and β-carotene (13.79 mg100g^-1) in C. tora were on par with A. fruiticosa (12.45 mg100g^-1 lycopene and 12.51 mg100g^-1 β-carotene). Anthocyanin content was highest in T. portulacifolium (23.62 mg100g^-1). The antioxidant activity was estimated using three assays and the maximum antioxidant activity was recorded in C. tora with lowest IC₅₀ values of 431.94 µgmL^-1, 30.58 µgmL^-1 and 107.59 µgmL^-1 in DPPH, FRAP and ABTS assays, respectively. Among the three wild edible plants, C. tora recorded the highest concentration of bioactive compounds and antioxidant capacity.

01 Mar 2025·International Journal of Biological Macromolecules

Interactions between protein Z and lycopene: A win-win scenario for both security and stability

Article

Author: Lv, Chenyan ; Gao, Yang ; Liu, Hanhan ; Lin, Junyu ; Sun, Mingyang ; Zhao, Guanghua ; Zhang, Tuo

Malt protein Z (PZ), the main albumin in malt endosperm, exhibits trypsin inhibitory activity and has the ability to bind fat-soluble active molecules. However, its potential utilization as a food ingredient necessitates an evaluation of its allergenicity. Lycopene has many functional activities, such as antioxidant and treatment or alleviation of various diseases, but its tendency to degrade easily hinders its effective utilization. Therefore, this paper investigates the allergenicity of PZ and provides a win-win scenario that PZ interacts with lycopene. PZ interacts with lycopene through non-covalent interactions with a ratio of 4.07 ± 0.20, leading to the formation of homogenous particles with an increased absolute zeta potential, from -7.3 ± 0.2 to -20.0 ± 0.6. Unsurprisingly, the presence of lycopene alleviates the allergenicity of PZ by decreasing the IgE, mMcp-1 and vascular permeability, such as the plasma mMcp-1 decreased from 245.0 ± 5.2 ng/mL for the PZ group to 217.8 ± 4.1 ng/mL for the PZ-LYC group. To uncover the potential mechanism, the linear antigenic epitopes of PZ by ABCpred were predicted, which are almost the potential binding site of lycopene at PZ. On the other hand, PZ improved the storage stability of lycopene. The addition of PZ increased lycopene retention in solution from 14.9 ± 2.7 % to 65.5 ± 2.8 % over 10 days at room temperature with light exposure. These results provide foundations for PZ utilization concerning security, and give ways to protect bioactive molecules.

100 Deals associated with Lycopene

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic Syndrome	Phase 3	LB	Omicron Pharma SRL	31 Jan 2011
Prostatitis	Phase 3	US	National Cancer Institute	29 Feb 2008
Castration-Resistant Prostatic Cancer	Phase 3	US	National Cancer Institute	01 Feb 2006
Prostatic Intraepithelial Neoplasia	Phase 3	US	National Cancer Institute	01 Feb 2006
Metastatic Prostate Carcinoma	Phase 3	US	National Cancer Institute	31 Jan 2004
Aneurysm	Phase 3	GB	Cambridge Theranostics Ltd.	-
Inflammation	Phase 3	GB	Cambridge Theranostics Ltd.	-
Stroke	Phase 3	GB	Cambridge Theranostics Ltd.	-
Subarachnoid Hemorrhage	Phase 3	GB	Cambridge Theranostics Ltd.	-
Vasospasm, Intracranial	Phase 3	GB	Cambridge Theranostics Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCO_IOF_ESCEO2020	Not Applicable	Adjuvant	18	Lycopene (Ovariectomized)	(pxkqxokvsi) = gsiqjjdaao wqcaknqmqv (pzcqcdcmry, 28.0) View more	Positive	20 Aug 2020
				Ovariectomized+lycopene	(pxkqxokvsi) = vhubhorkkc wqcaknqmqv (pzcqcdcmry, 36.45) View more
NCT01443026 (CTgov)	Phase 2	Castration-Resistant Prostatic Cancer \| Prostatic Intraepithelial Neoplasia	66	Lycopene 30mg (Lycopene)	lwtzsudeeu(saxncqvrri) = qyjqlfzytg wlwfdunses (tchgdvusew, hosllyxgdg - nryzuxqkty) View more	-	04 Jun 2015
				Placebo (Placebo)	lwtzsudeeu(saxncqvrri) = hjsodmguda wlwfdunses (tchgdvusew, ysjnrlmmfw - ymimxisrxh) View more
[PP.02.42] (ESH2015)	Not Applicable	-	60	lycopene (Control Group)	yzlxgsubfv(opsgjqpybd) = cuzwhbjfhn behsocthsb (qxrffuorgm ) View more	Positive	01 Jun 2015
				lycopene (Intervention Group)	yzlxgsubfv(opsgjqpybd) = nkwoijnxje behsocthsb (qxrffuorgm ) View more
Pubmed \| Urology	Phase 2	Castration-Resistant Prostatic Cancer serum prostate-specific antigen elevation	46	Tomato-Based, Lycopene-Containing Intervention	gqswvlvojd(hwppbwanxz) = 1 patient died of a cancer-related hemorrhage gulilkqxhq (psbddkbcuk )	Negative	01 Feb 2007